INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

EMA Backs Two New Options for NSCLC

Save Like Comments Compare coverage

Summary

The CHMP has backed Zybrivo plus chemotherapy for first-line nonsquamous NSCLC and Aumseqa for advanced EGFR-mutated disease. Medscape News Europe

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    EMA Backs Two New Options for NSCLC

    The CHMP has backed Zybrivo plus chemotherapy for first-line nonsquamous NSCLC and Aumseqa for advanced EGFR-mutated disease. Medscape News Europe

Comments

Comments need JavaScript.